Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy-Reference-Cited by-同舟云学术

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy

Published:2014-11-11 Issue:3 Volume:148 Page:563-570
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Mortimer Joanne,Jung Jae,Yuan Yuan,Kruper Laura,Stewart Daphne,Chung Samuel,Yu Kim Wai,Mendelsohn Mary,D’Apuzzo Massimo,Tegtmeier Bernard,Dadwal Sanjeet

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-014-3190-5.pdf

Reference26 articles.

1. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(19):2078–2099. doi: 10.1200/jco.2013.54.0948

2. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. doi: 10.1056/NEJMoa064320

3. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30(21):2585–2592. doi: 10.1200/jco.2011.35.6725

4. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. doi: 10.1056/NEJMoa1209124

5. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. doi: 10.1056/NEJMoa1113216

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose-volume predictors of radiation dermatitis in patients undergoing radiotherapy after radical mastectomy for breast cancer;2024-01-03

2. Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients;Breast Cancer Research and Treatment;2023-10-13

3. Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma;Molecular Oncology;2023-07-14

5. The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy;Journal of Cutaneous Pathology;2022-10-03